Robuta

https://www.aicuris.com/ Homepage - Aicuris Apr 16, 2026 - Delivering Novel Anti-Viral Therapies to patients with weakened immune systems We are driven to meet the needs of the growing population of immunocompromised pe homepageaicuris https://www.aicuris.com/clinical-trials/ Clinical Trials - Aicuris Oct 16, 2025 - Clinical Trials Developing the Next Generation of Therapies to Combat Viral Infections At Aicuris, our commitment to pioneering therapies in infectious disease clinical trialsaicuris https://www.amrindustryalliance.org/member/aicuris-anti-infective-cures-gmbh-germany/ AiCuris Anti-infective Cures GmbH, Germany - AMR Industry Alliance anti infectiveamr industryaicuriscuresgmbh https://www.aicuris.com/press-release/aicuris-presents-positive-phase-2-results-for-pritelivir-and-favorable-phase-1-safety-data-for-aic468-at-id-week-2025/ Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for... Oct 20, 2025 - Aicuris today announced the presentation of new clinical data at ID Week 2025, highlighting progress across two key antiviral programs. Phase 2 results for prit aicurispresentspositivephaseresults https://www.aicuris.com/publications/ Publications - Aicuris publicationsaicuris https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/biopharma-news/asahi-kasei-completes-acquisition-of-aicuris/ Asahi Kasei completes acquisition of Aicuris - European Pharmaceutical Manufacturer Apr 20, 2026 - Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective Cures (Aicuris), a German-based... asahi kaseicompletes acquisitioneuropean pharmaceuticalaicurismanufacturer https://www.aicuris.com/products/ Products - Aicuris productsaicuris https://www.aicuris.com/press-release/aicuris-receives-fda-priority-review-for-pritelivir-nda-and-presents-new-phase-3-data-at-escmid-2026/ Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID... Apr 16, 2026 - Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026 Aicuris today announced that the U.S. Food and Drug Adminis receives fdapresents newaicurispriorityreview https://www.aicuris.com/press-release/aicuris-announces-pritelivir-phase-3-hsv-data-to-be-presented-as-late-breaking-oral-presentation-at-tandem/ Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at... Jan 29, 2026 - Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem Aicuris will share Phase 3 data from for its lead can late breakingaicurisannouncesphasehsv https://www.aicuris.com/scientific-presentations/ Scientific Presentations - Aicuris scientificpresentationsaicuris https://www.aicuris.com/contact/ Contact - Aicuris Mar 11, 2026 - Contact From concept to cure: advancing therapies to protect immunocompromised patients At Aicuris, we are committed to developing life-saving therapies for imm aicuris https://www.aicuris.com/about/ About - Aicuris May 14, 2026 - About Addressing the critical needs of immunocompromised patients Company Overview Aicuris is at the forefront of developing innovative therapies to protect ind aicuris https://www.aicuris.com/privacy-notice/ Privacy Notice - Aicuris Jan 15, 2026 - PRIVACY NOTICE Data protection is of high concern to Aicuris. For this reason, the processing of data from our website visitors, patients and customers in gener privacy noticeaicuris https://www.aicuris.com/imprint/ Imprint - Aicuris Feb 25, 2025 - Imprint AiCuris Anti-infective Cures AG Friedrich-Ebert-Str. 475 Building 302 42117 Wuppertal Germany Phone +49 (0)202 317 63 - 0 Fax +49 (0)202 317 63 - 1177 M imprintaicuris https://www.aicuris.com/news-events/ News & Events - Aicuris news eventsaicuris https://www.aicuris.com/careers/ Careers - Aicuris Feb 14, 2025 - Careers Join us in redefining the future of infection care Aicuris is dedicated to meeting the needs of the growing population of immunocompromised people who r careersaicuris